Suppr超能文献

炎症性肠病中的病毒感染:正确管理的技巧与窍门。

Viral infections in inflammatory bowel disease: Tips and tricks for correct management.

机构信息

Humanitas Clinical and Research Center, IRCCS, Rozzano 20089, Milano, Italy.

Department of Hepato-Gastroenterology and Inserm U954, University Hospital of Nancy, Lorraine University, Nancy 54511, France.

出版信息

World J Gastroenterol. 2021 Jul 21;27(27):4276-4297. doi: 10.3748/wjg.v27.i27.4276.

Abstract

Over the past decades, the treatment of inflammatory bowel diseases (IBD) has become more targeted, anticipating the use of immune-modifying therapies at an earlier stage. This top-down approach has been correlated with favorable short and long-term outcomes, but it has also brought with it concerns regarding potential infectious complications. This large IBD population treated with immune-modifying therapies, especially if combined, has an increased risk of severe infections, including opportunistic infections that are sustained by viral, bacterial, parasitic, and fungal agents. Viral infections have emerged as a focal safety concern in patients with IBD, representing a challenge for the clinician: they are often difficult to diagnose and are associated with significant morbidity and mortality. The first step is to improve effective preventive strategies, such as applying vaccination protocols, adopt adequate prophylaxis and educate patients about potential risk factors. Since viral infections in immunosuppressed patients may present atypical signs and symptoms, the challenges for the gastroenterologist are to suspect, recognize and diagnose such complications. Appropriate treatment of common viral infections allows us to minimize their impact on disease outcomes and patients' lives. This practical review supports this standard of care to improve knowledge in this subject area.

摘要

在过去几十年中,炎症性肠病(IBD)的治疗变得更加具有针对性,在更早的阶段就开始使用免疫调节疗法。这种自上而下的方法与良好的短期和长期结果相关,但也带来了对潜在感染并发症的担忧。 接受免疫调节疗法治疗的大量 IBD 患者,尤其是联合治疗的患者,严重感染的风险增加,包括由病毒、细菌、寄生虫和真菌引起的机会性感染。病毒感染已成为 IBD 患者关注的焦点安全问题,这对临床医生来说是一个挑战:它们通常难以诊断,并且与显著的发病率和死亡率相关。第一步是改善有效的预防策略,例如应用疫苗接种方案、采取适当的预防措施并教育患者潜在的风险因素。由于免疫抑制患者中的病毒感染可能表现出非典型的体征和症状,因此胃肠病学家的挑战是怀疑、识别和诊断这些并发症。对常见病毒感染的适当治疗可以最大限度地减少它们对疾病结果和患者生活的影响。本实践综述支持这一护理标准,以提高该领域的知识水平。

相似文献

1
Viral infections in inflammatory bowel disease: Tips and tricks for correct management.
World J Gastroenterol. 2021 Jul 21;27(27):4276-4297. doi: 10.3748/wjg.v27.i27.4276.
2
Updates on vaccinating the inflammatory bowel disease patient.
Expert Rev Gastroenterol Hepatol. 2019 Mar;13(3):229-239. doi: 10.1080/17474124.2019.1565993. Epub 2019 Jan 21.
3
Diagnostic and vaccine strategies to prevent infections in patients with inflammatory bowel disease.
J Infect. 2017 May;74(5):433-441. doi: 10.1016/j.jinf.2017.02.009. Epub 2017 Mar 2.
4
The risk for opportunistic infections in inflammatory bowel disease with biologics: an update.
Expert Rev Gastroenterol Hepatol. 2018 Nov;12(11):1101-1108. doi: 10.1080/17474124.2018.1530983. Epub 2018 Oct 10.
6
Vaccinating the inflammatory bowel disease patient.
Expert Rev Gastroenterol Hepatol. 2015 Jan;9(1):91-102. doi: 10.1586/17474124.2014.934672. Epub 2014 Aug 27.
7
Prevalence of hepatitis B and C and factors for infection and nonimmune in inflammatory bowel disease patients in China.
Eur J Gastroenterol Hepatol. 2017 May;29(5):509-515. doi: 10.1097/MEG.0000000000000838.
8
Prevention and management of infectious complications in IBD.
Dig Dis. 2012;30(4):408-14. doi: 10.1159/000338143. Epub 2012 Jul 12.
9
Infection-related hospitalizations in the first year after inflammatory bowel disease diagnosis.
J Dig Dis. 2016 Sep;17(9):610-617. doi: 10.1111/1751-2980.12397.

引用本文的文献

2
Favipiravir Protects Enterocytes From Cell Death After Inflammatory Storm.
Cureus. 2023 Oct 21;15(10):e47417. doi: 10.7759/cureus.47417. eCollection 2023 Oct.
3
Iranian Consensus Guideline for Pharmacotherapy with Biologics and Small Molecules Drugs in Adults with Inflammatory Bowel Diseases.
Middle East J Dig Dis. 2023 Apr;15(2):83-106. doi: 10.34172/mejdd.2023.327. Epub 2023 Apr 30.
6
Association Between Inflammatory Bowel Disease and Viral Infections.
Curr Microbiol. 2023 Apr 27;80(6):195. doi: 10.1007/s00284-023-03305-0.
8
Liver-side of inflammatory bowel diseases: Hepatobiliary and drug-induced disorders.
World J Hepatol. 2021 Dec 27;13(12):1828-1849. doi: 10.4254/wjh.v13.i12.1828.

本文引用的文献

5
Hepatitis-B Vaccine Response in Inflammatory Bowel Disease Patients: A Systematic Review and Meta-analysis.
Inflamm Bowel Dis. 2021 Oct 18;27(10):1610-1619. doi: 10.1093/ibd/izaa353.
6
Impact of HIV Infection on the Course of Inflammatory Bowel Disease and Drug Safety Profile: A Multicenter GETAID Study.
Clin Gastroenterol Hepatol. 2022 Apr;20(4):787-797.e2. doi: 10.1016/j.cgh.2020.12.023. Epub 2020 Dec 24.
9
Why Do Immunosuppressed Patients with Inflammatory Bowel Disease Not Seem to Be at a Higher Risk of COVID-19?
Dig Dis Sci. 2021 Sep;66(9):2855-2864. doi: 10.1007/s10620-020-06624-5. Epub 2020 Oct 19.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验